HIGHLIGHTS
- who: Yin Yin and collaborators from the State Key Laboratory of Molecular Oncology, National Center, National Clinical Research Center for Beijing, China have published the paper: Drug Repurposing Applications to Overcome Male Predominance via Targeting G2/M Checkpoint in Human Esophageal Squamous Cell Carcinoma, in the Journal: Cancers 2022, x of /2022/
- what: The authors first validated the sex bias of the G2/M checkpoint pathway in ESCC and then determined that G2/M targets may be included in combination therapy for patients to improve the efficacy of ESCC treatment. with regard to jurisdictional claims . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.